How business insights drive clinical and commercial innovation

12 June 2017

The term ‘innovation’ has come to be associated with capability to deliver value and set companies apart from the competition.

Indeed, pharma companies need to constantly innovate to retain prominence in the industry, and the results of the Pharma Innovation Index (PII) for 2017 clearly demonstrate this. The PII has ranked companies for the past eight years, but for the first time, Biogen (Nasdaq: BIIB) tops the list. Mike Rea, chief executive of IDEA Pharma, the innovators of the PII, shares how Biogen reached the top, as well as some key considerations for other pharma companies wishing to deliver innovation.

Why Biogen sits on top

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK